Among sufferers with a 351-to-500 CD4+ count, the median count per cubic millimeter was 422 cells in the early-therapy group and 431 cells in the deferred-therapy group; among individuals with a more-than-500 CD4+ count, the median count per cubic millimeter was 679 cells in the early-therapy group and 664 cells in the deferred-therapy group. In the subgroup of patients for whom data were available, fewer individuals with a past history of injection-drug make use of and HCV disease were in the early-therapy group.Park says. Early evidence indicates the RNS device may be most effective for foci in the medial temporal lobe, an area deep inside the brain involved in memory, where surgery is not a choice, he says. A small number of new drugs, with fewer side effects generally, have become obtainable in the last few years also, giving patients and their doctors more options, he says. MCG has begun studies of three additional anti-seizure medications.